Literature DB >> 25584170

Elemental diet and the nutritional treatment of Crohn's disease.

John Hunter1.   

Abstract

Entities:  

Year:  2015        PMID: 25584170      PMCID: PMC4285926     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol Bed Bench        ISSN: 2008-2258


× No keyword cloud information.
The study by Rostami and Al Dulami in the present edition of the journal adds a further indication for the use of Elemental diet in Inflammatory Bowel Disease, namely the treatment of a high output stoma (1). The authors stress the value of such treatment in a range of disorders, but its main role remains in the treatment of Crohn’s disease. The value of enteral feeds in Crohn’s disease was first reported over 30 years ago (2,3).  However, despite general agreement of the effectiveness of enteral feeding and the difficulties generally encountered in managing Crohn’s disease, diet is still infrequently used.  This may partly be an effect of the intense publicity given to treatment with biological agents in recent years, but it also reflects a number of other factors. Perhaps the most important of these has been failure to understand the mechanisms by which enteral feeding works.  Crohn’s disease has long been a puzzle to gastroenterologists but the clouds are gradually clearing and studies on the effects of enteral feed have helped considerably. Although in health we live in peace with our microflora, the colonic microflora is abnormal in Crohn’s disease (4). This may lead to production of toxic chemicals such as alcohols, aldehydes and the ethyl esters of fatty acids (5).  It is believed that this is the reason for the loss of normal immune tolerance to the gut flora in Crohn’s disease, which results in the coating of faecal bacteria by immunoglobulin (6-8).  Elemental diet has been shown to reduce the production of bacterial metabolites (5) within 2 weeks and significantly to reduce bacterial coating with immunoglobulin (8). Thus enteral feeds act directly on the microbiota.  Although many still assume that their effects must be related to food allergy, this is not the case and manifestations of genuine IgE and IgG food allergies do not apply. Overall, the results of enteral feeding are excellent with 80-100% of compliant patients going into remission within 2-3 weeks.  The efficacy of these feeds appears to be more closely related to the amount of energy coming from long chain triglyceride rather than the presentation of nitrogen (9). Such results compare favourably with those achieved by treatment of Crohn’s disease with immunosuppression.  Why then, is the nutritional approach so infrequently used? Clearly, patient compliance is one factor.  In most studies approximately 25% are unwilling to restrict their nutritional intake to a liquid feed for as long as 2-3 weeks and 5% in our experience find the taste unpalatable.  This accounts for the ‘failure’ of enteral feeding to appear superior to corticosteroids in intention to treat studies (10).  However, most patients who have experienced difficulties with pharmacological treatments are willing to accept the inconvenience involved. There are also disagreements about how patients should be managed when they achieve remission.  The reintroduction of normal foodstuffs is still controversial, but the value of detecting specific food intolerances and building up a personalised exclusion diet for long term remission is well documented (11-13). A diet low in fat and fibre (LOFFLEX) has been shown to be highly effective with nearly 60% of patients in remission after 2 years (14).  Foods involved vary from patient to patient but may include cereals such as wheat, maize and oats, dairy products, pork, onions and yeast. The process of food testing involves trial and error and requires patience. It is therefore essential that dietitians are available to ensure diets remain nutritionally adequate. Such specialist support is not available in all centres and some gastroenterologists lack confidence in managing nutrition problems. This may deter many from trying this approach, despite its proven lack of side effects such as osteoporosis and safety in pregnancy (15, 16). However, surely it must be available in tertiary centres dealing with complex refractory cases of Crohn’s disease.
  13 in total

1.  Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.

Authors:  C Manichanh; L Rigottier-Gois; E Bonnaud; K Gloux; E Pelletier; L Frangeul; R Nalin; C Jarrin; P Chardon; P Marteau; J Roca; J Dore
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

2.  Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12.

Authors:  R Duchmann; E Schmitt; P Knolle; K H Meyer zum Büschenfelde; M Neurath
Journal:  Eur J Immunol       Date:  1996-04       Impact factor: 5.532

3.  Breakdown of tolerance to the intestinal bacterial flora in inflammatory bowel disease (IBD)

Authors:  T T MacDonald
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

4.  Treatment of active Crohn's disease by exclusion diet: East Anglian multicentre controlled trial.

Authors:  A M Riordan; J O Hunter; R E Cowan; J R Crampton; A R Davidson; R J Dickinson; M W Dronfield; I W Fellows; S Hishon; G N Kerrigan
Journal:  Lancet       Date:  1993-11-06       Impact factor: 79.321

5.  Elemental diet as primary treatment of acute Crohn's disease: a controlled trial.

Authors:  C O'Moráin; A W Segal; A J Levi
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-23

6.  Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn's disease.

Authors:  S J Middleton; J T Rucker; G A Kirby; A M Riordan; J O Hunter
Journal:  Clin Nutr       Date:  1995-08       Impact factor: 7.324

7.  Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases.

Authors:  Christopher Walton; Dawn P Fowler; Claire Turner; Wenjing Jia; Rebekah N Whitehead; Lesley Griffiths; Claire Dawson; Rosemary H Waring; David B Ramsden; Jeffrey A Cole; Michael Cauchi; Conrad Bessant; John O Hunter
Journal:  Inflamm Bowel Dis       Date:  2013-09       Impact factor: 5.325

8.  Immunoglobulin coating of faecal bacteria in inflammatory bowel disease.

Authors:  Laurens A van der Waaij; Frans G M Kroese; Annie Visser; Gerardus F Nelis; Bram D Westerveld; Peter L M Jansen; John O Hunter
Journal:  Eur J Gastroenterol Hepatol       Date:  2004-07       Impact factor: 2.566

9.  Practical aspects of enteral nutrition in the management of Crohn's disease.

Authors:  K Teahon; M Pearson; A J Levi; I Bjarnason
Journal:  JPEN J Parenter Enteral Nutr       Date:  1995 Sep-Oct       Impact factor: 4.016

10.  Elemental diets role in treatment of high ileostomy output and other gastrointestinal disorders.

Authors:  Kamran Rostami; David Al Dulaimi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015
View more
  2 in total

1.  Intestinal development and homeostasis require activation and apoptosis of diet-reactive T cells.

Authors:  Alexander Visekruna; Sabrina Hartmann; Yasmina Rodriguez Sillke; Rainer Glauben; Florence Fischer; Hartmann Raifer; Hans Mollenkopf; Wilhelm Bertrams; Bernd Schmeck; Matthias Klein; Axel Pagenstecher; Michael Lohoff; Ralf Jacob; Oliver Pabst; Paul William Bland; Maik Luu; Rossana Romero; Britta Siegmund; Krishnaraj Rajalingam; Ulrich Steinhoff
Journal:  J Clin Invest       Date:  2019-04-02       Impact factor: 14.808

2.  Metabolomics activity screening of T cell-induced colitis reveals anti-inflammatory metabolites.

Authors:  J Rafael Montenegro-Burke; Bernard P Kok; Carlos Guijas; Xavier Domingo-Almenara; Clara Moon; Andrea Galmozzi; Seiya Kitamura; Lars Eckmann; Enrique Saez; Gary E Siuzdak; Dennis W Wolan
Journal:  Sci Signal       Date:  2021-09-28       Impact factor: 8.192

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.